Aktis Oncology is a clinical-stage company developing targeted alpha radiopharmaceuticals for solid tumors. Its approach uses miniprotein radioconjugates designed to deliver actinium-225 to tumor markers such as Nectin-4 and B7-H3. Lead candidates are in early clinical development for cancers including urothelial, breast, lung, and other solid tumors. The company collaborates with partners on discovery and manufacturing of these precision radiotherapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1.6 | — | -18.1 | — |
| Q3 2025 | 1.6 | — | -15.5 | — |
| Q4 2025 | 1.9 | — | -15.1 | — |
| Q1 2026 | 3.2 | — | -18.3 | — |
| Q2 2026 | 3.4 | 111.4% | -24.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Paysign, Inc. (PAYS), Cullinan Therapeutics, Inc. (CGEM), Monte Rosa Therapeutics, Inc. (GLUE), Daily Journal Corporation (DJCO), Strategy Inc (STRD), Liberty Capital Corporation (GLIBK)